0000000000667899

AUTHOR

Joerg Rahnenfuehrer

showing 4 related works from this author

Prognostic significance of the chemokine CXCL13 in node-negative breast cancer

2013

615 Background: The chemokine CXCL13 is chemotactic for B cells. We examined the prognostic significance of CXCL13 mRNA expression in node-negative breast cancer. Methods: Microarray based gene-expression data for CXCL13 (205242_at) were analysed in four previously published cohorts (Mainz, Rotterdam, Transbig, Yu) of node-negative breast cancer patients not treated with adjuvant therapy (n=824). A meta-analysis of previously published cohorts was performed using a random effects model. Prognostic significance of CXCL13 on metastasis-free survival (MFS) was examined in the whole cohort and in different molecular subtypes (ER+/HER2-, ER-/HER2-, HER2+). Independent prognostic relevance was a…

OncologyCancer Researchmedicine.medical_specialtyChemokineMicroarraybiologybusiness.industryMrna expressionObstetrics and GynecologyChemotaxismedicine.diseaseNode negativeBreast cancerOncologyInternal medicineMaternity and MidwiferyImmunologyCancer researchbiology.proteinMedicineCXCL13businessGeburtshilfe und Frauenheilkunde
researchProduct

Prognostic significance of Focal Adhesion Kinase (FAK) in node-negative breast cancer.

2015

552 Background: Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase playing an important role as a key mediator for signal transduction. We examined the subtype specific prognostic signifi...

CYTOPLASMIC TYROSINE KINASECancer ResearchPathologymedicine.medical_specialtybusiness.industrymedicine.diseaseNode negativeFocal adhesionMediatorBreast cancerOncologymedicineCancer researchSignal transductionbusinessJournal of Clinical Oncology
researchProduct

Prediction of late metastasis in node-negative breast cancer.

2012

10551 Background: Prediction of late metastasis is of clinical relevance in breast cancer. However, systematic genome-wide studies to identify genes associated with increased risk of metastasis 5 or more years after surgery are scarce. Methods: We examined the natural course of disease in three previously published cohorts (Mainz, Rotterdam, Transbig) including 766 node-negative breast cancer patients with gene array data who did not receive systemic chemotherapy in the adjuvant setting. We established a Cox regression based method adjusted for multiple testing that identified genes predicting late metastasis (5 or more years after surgery). Only those genes were accepted that showed simil…

CA15-3OncologyCancer Researchmedicine.medical_specialtybusiness.industryCancermedicine.diseaseMetastasisNode negativeBreast cancerIncreased riskOncologyInternal medicinemedicineClinical significancebusinessJournal of Clinical Oncology
researchProduct

Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.

2014

620 Background: The transcription factor IRF4 (interferon regulating factor 4) regulates immunoglobulin class switch recombination as well as plasma cell differentiation. We examined the prognostic significance of IRF4 mRNA expression in node-negative breast cancer. Methods: Microarray based gene-expression data for IRF4 (204562_at) were analysed in four previously published cohorts (Mainz, Rotterdam, Transbig, Yu) of node-negative breast cancer patients not treated with adjuvant therapy (n=824). A meta-analysis of previously published cohorts was performed using a random effects model. Prognostic significance of IRF4 on metastasis-free survival (MFS) was examined in the whole cohort and in…

Cancer ResearchMicroarraybusiness.industrymedicine.diseaseBreast cancerOncologyInterferonPlasma cell differentiationImmunologyCancer researchmedicineAdjuvant therapyAurora Kinase Askin and connective tissue diseasesbusinessTranscription factorIRF4medicine.drugJournal of Clinical Oncology
researchProduct